Browsing by Author Triyatni, M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 3 to 9 of 9 < previous 
TitleAuthor(s)Issue DateViews
 
RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy
Proceeding/Conference:Journal of Hepatology
Yuen, RMFGane, EKim, DJChan, HSurujbally, BPavlovic, VTriyatni, MGrippo, JKim, HJLeerapun, ALim, THLim, YSTanwandee, TKim, WCheng, WHu, THWat, C
2020
 
Safety, pharmacokinetic, pharmacodynamic and viral data after 6-weeks of dosing with TLR7 agonist RO7020531 in chronic hepatitis B patients
Proceeding/Conference:Hepatology
Yuen, RMFBalabanska, RIAgarwal, KZhu, YHGrippo, JJin, YYJiang, QDTriyatni, MUpmanyu, RGlavini, KRacek, TGane, EJ
2019
34
 
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, RMFZhou, XGane, ESchwabe, CTanwandee, TFeng, SJin, YYTriyatni, MLemenuel-Diot, ACosson, VXue, ZHKazma, RBo, QY
2021
 
The pharmacokinetic and safety profiles of RO7445482 SIRNA are similar between Asian and nonAsian healthy volunteers and chronic hepatitis B patients in a phase 1 Study
Proceeding/Conference:Poster presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology
Gane, EJGuerreiro, NBuatois, SKim, WYoon, J-HLim, THSiever, WThompson, ASukeepaisarnjaroen, WTangkijvanich, PSchwabe, CBrown, BDTriyatni, MBo, QYAchneck, HYuen, RMF
2021
 
TLR7 agonist ro7020531 triggers immune activation after multiple doses in chronic hepatitis B patients
Proceeding/Conference:Hepatology
Gane, EJAgarwai, KBalabanska, RZhu, YLu, GGrippo, JFJin, YTriyatni, MFolitar, IUpmanyu, RGlavini, KCoakley, ERacek, TYuen, RMF
2018
 
TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial
Journal:The Lancet Infectious Diseases
Yuen, MFBalabanska, RCottreel, EChen, ETDuan, DJiang, QDPatil, ATriyatni, MUpmanyu, RZhu, YHCanducci, FGane, EJ
22-Mar-2023
 
Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naive chronic hepatitis B patients: 48-week treatment and posttreatment follow-up. Poster Presentation (SAT427)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Yuen, RMFBalabanska, RHou, JLGane, EJLim, THZhang, WHXie, QKomolmit, PLeerapun, AYang, S-SYeh, C-TZhang, WZhou, XXue, ZHTriyatni, MChen, ELi, RBo, Q-Y
2022
Showing results 3 to 9 of 9 < previous